LQDA · Liquidia Corporation

The thesis

The case for Liquidia Corporation is that YUTREPIA, its inhaled treprostinil powder, can keep growing on pulmonary arterial hypertension (PAH) alone now that the 13 October 2026 settlement with United Therapeutics has ended the patent fight. The Q3 2026 report on 10 November 2026 is the first test. The sales figure is already pre-announced, so the commentary on pulmonary hypertension associated with interstitial lung disease (PH-ILD) carries the news.

Liquidia's 8-K of 13 October 2026 put the net cost at $380.7 million in installments across 2026 and 2027. It also gave preliminary Q3 YUTREPIA net product sales of $222.7 million, against $170.4 million in Q2, and cash of $396.1 million on 30 September 2026.

The narrative is maturing: the settlement is well known, the adjusted close moved only from $45.44 on 27 October 2026 to $44.49 on 5 November 2026, and the next new fact is the 10 November 2026 report. A daily close below $33 would show the rebound has failed.

Bullish and bearish views on Liquidia Corporation

The bull case on Liquidia Corporation (LQDA), in brief: The patent overhang is settled. The bear case: The settlement actively moves PH-ILD patients away.

Bull case

• The patent overhang is settled. The settlement resolves all six lawsuits and keeps YUTREPIA available for PAH patients without interruption (Liquidia 8-K, 13 October 2026). United Therapeutics' 4 November 2026 release says the related Sandoz matter was dismissed on 28 October 2026.

• The rival's report confirms the competition. United Therapeutics reported on 4 November 2026 that nebulized Tyvaso fell 12% to $125.3 million in Q3 on lower US quantities. It said competitive therapies hurt nebulized Tyvaso, Tyvaso DPI and Remodulin.
• The business was profitable before the settlement. Liquidia reported Q1 2026 earnings of $0.52 a share on sales of $132.865 million (Benzinga, 11 May 2026), and $396.1 million in cash on 30 September 2026.
• Most mid-October targets sit above the price. BTIG's target is $70, HC Wainwright's is $65 and Needham's is $58, all set on 14 October 2026 or 15 October 2026 (Benzinga), against the $44.49 close of 5 November 2026.

Bear case

• The settlement actively moves PH-ILD patients away. United Therapeutics' 8-K says Liquidia must tell practitioners that PH-ILD patients should move to another therapy and ask payers to deny PH-ILD prior authorizations. Sales under the PH-ILD label must cease once the FDA approves the amendment.
• The revenue at risk is unmeasured. Liquidia's 13 October 2026 8-K exhibit does not split Q3 sales between PAH and PH-ILD. The 10 November 2026 report may or may not supply that split.
• Payments nearly match cash. The net $380.7 million compares with $396.1 million in cash on 30 September 2026. United Therapeutics' 8-K shows $185 million due within 30 business days, $10 million coming back, and $72.7 million each by 1 February 2027 and 30 April 2027.
• Tyvaso is still growing. United Therapeutics reported Tyvaso DPI up 13% to $378.5 million in Q3 2026, and total Tyvaso of $503.8 million against $452.6 million in Q2. A Jefferies analyst told Reuters the settlement should improve visibility on Tyvaso growth in PH-ILD.
• One product carries the company. YUTREPIA was $170.4 million of $171.7 million total revenue in Q2 2026 (company results, 12 August 2026).
• One target sits below the price. Wells Fargo kept Equal-Weight with a $33 target on 14 October 2026 (Benzinga).

Price setup

The adjusted close on 5 November 2026 was $44.49, which is 51.1% below the 52-week high of $91.03. The three-month change is also -51.1%. The shares closed at $33.94 on 14 October 2026, the day after the settlement.

The 14-day relative strength index (RSI), a momentum gauge where readings above 70 are commonly called overbought, eased from 90.7 on 27 October 2026 to 70.9 on 5 November 2026. Crowding shows mainly in that reading and in the earnings date three sessions after the last close. Company news through 5 November 2026 shows no share offering or debt financing.

Catalysts, next 30 days

• 10 November 2026: Liquidia Q3 2026 results, with a webcast at 8:30 a.m. Eastern (company release, 3 November 2026). It confirms or revises the $222.7 million and shows what management says about PH-ILD patients leaving.
• ~24 November 2026, est.: The net $175 million initial payment, due within 30 business days of 13 October 2026. Under United Therapeutics' 8-K, the parties seek dismissal of the covered cases within ten days after payment.
• No date disclosed: FDA action on the supplement removing PH-ILD from the label. Liquidia may keep selling under the current label until the FDA approves it (United Therapeutics 8-K).
• 1 February 2027: The first $72.7 million installment (United Therapeutics 8-K).

Elapsed catalysts

• ~2027-01, est.: Preliminary full-year sales, if Liquidia repeats its 9 January 2026 practice. This would give an early measure of Q4 sales, the first quarter after the settlement. (passed 301d ago)

What would change the view

The case breaks if YUTREPIA proves unable to grow without PH-ILD. A full Q3 figure below the preliminary $222.7 million, or Q4 sales well below it, would show that. So would a disclosure that PH-ILD made up most of the patients on the drug.

A share offering or debt financing on poor terms before the 1 February 2027 installment would show the payments outran the cash. A missed payment or a dispute over the settlement would reopen the legal risk. On price, a daily close below $33, under the $33.94 close of 14 October 2026, would erase the post-settlement recovery.

A PAH-only growth figure in the 10 November 2026 report, or preliminary Q4 sales close to the Q3 level, would strengthen the case.

What it trades with

Liquidia trades on its own legal and sales news. The rebound from $33.94 on 14 October 2026 followed a company settlement, not a market-wide event. United Therapeutics is the closest read-across, since Tyvaso and YUTREPIA are both inhaled treprostinil, and its reports bear directly on Liquidia. Its 4 November 2026 report showed both competitive pressure on nebulized Tyvaso and growth in Tyvaso DPI.